Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma

Journal of Surgical Oncology

Volumn 97, Issue 3, 2008, Pages 259-266

  Kaseta, Maria Kyriaki A ^a,c   Khaldi, Lubna ^b   Gomatos, Ilias P ^a   Tzagarakis, George P ^a   Alevizos, Leonidas ^a   Leandros, Emmanuel ^a   Papagelopoulos, Panayiotis J ^a   Soucacos, Panayiotis N ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^c NONE   (Greece)

Author keywords

Apoptosis; Bax; bcl 2; Osteosarcoma; p53; Prognosis

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 39749134998     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20913     Document Type: Article

References (33)

1. 1 Copeland MM, Sutow WW: Osteogenic sarcoma: The past, present, and future. Int Adv Surg Oncol 1979 ; 2: 177–200.
2. 2 Gokgoz N, Wunder JS, Mousses S, et al.: Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer 2001 ; 92: 2181–2189.
3. 3 Pruneri G, Pignataro L, Carboni N, et al.: Clinical relevance of p53 and bcl‐2 protein over‐expression in laryngeal squamous‐cell carcinoma. Int J Cancer 1998 ; 79: 263–268.
4. 4 Buglioni S, D'Agnano I, Cosimelli M, et al.: Evaluation of multiple bio‐pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl‐2. Int J Cancer 1999 ; 84: 545–552.
5. 5 Bauer JJ, Sesterhenn IA, Mostofi FK, et al.: Elevated levels of apoptosis regulator proteins p53 and bcl‐2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996 ; 156: 1511–1516.
6. 6 Friess H, Lu Z, Graber HU, et al.: Bax, but not bcl‐2, influences the prognosis of human pancreatic cancer. Gut 1998 ; 43: 414–421.
7. 7 Dimitrakakis C, Konstadoulakis M, Messaris E, et al.: Molecular markers in breast cancer: Can we use c‐erbB‐2, p53, bcl‐2 and bax gene expression as prognostic factors? Breast 2002 ; 11: 279–285.
8. 8 Pakos EE, Kyzas PA, Ioannidis JP: Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: A meta‐analysis. Clin Cancer Res 2004 ; 10: 6208–6214.
9. 9 Ferrari S, Bertoni F, Zanella L, et al.: Evaluation of P‐glycoprotein, HER‐2/ErbB‐2, p53, and Bcl‐2 in primary tumor and metachronous lung metastases in patients with high‐grade osteosarcoma. Cancer 2004 ; 100: 1936–1942.
10. 10 Claude L, Rousmans S, Carrie C, et al.: Standards and Options for the use of radiation therapy in the management of patients with osteosarcoma. Bull Cancer 2005 ; 92: 891–906.
11. 11 Picci P, Bacci G, Campanacci M, et al.: Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 1985 ; 56: 1515–1521.
12. 12 Skirnisdottir I, Seidal T, Gerdin E, et al.: The prognostic importance of p53, bcl‐2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer 2002 ; 12: 265–276.
13. 13 Davis AM, Bell RS, Goodwin PJ: Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 1994 ; 12: 423–431.
14. 14 Labat‐Moleur F, Guillermet C, Lorimier P, et al.: TUNEL apoptotic cell detection in tissue sections: Critical evalua tion and improvement critical evaluation and improvement. J Histochem Cytochem 1998 ; 46: 327–334.
15. 15 Bieling P, Rehan N, Winkler P, et al.: Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996 ; 14: 848–858.
16. 16 Kawauchi S, Fukuda T, Oda Y, et al.: Prognostic significance of apoptosis in synovial sarcoma: Correlation with clinicopathologic parameters, cell proliferative activity, and expression of apoptosis‐related proteins. Mod Pathol 2000 ; 13: 755–765.
17. 17 Mousses S, McAuley L, Bell RS, et al.: Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol 1996 ; 9: 1–6.
18. 18 Junior AT, de Abreu Alves F, Pinto CA, et al.: Clinicopathological and immunohistochemical analysis of twenty‐five head and neck osteosarcomas. Oral Oncol 2003 ; 39: 521–530.
19. 19 Tsai JY, Aviv H, Benevenia J, et al.: HER‐2/neu and p53 in osteosarcoma: An immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest 2004 ; 22: 16–24.
20. 20 Nakashima H, Nishida Y, Sugiura H, et al.: Telomerase, p53 and PCNA activity in osteosarcoma. Eur J Surg Oncol 2003 ; 29: 564–567.
21. 21 Kawaguchi K, Oda Y, Sakamoto A, et al.: Molecular analysis of p53, MDM2, and H‐ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. Mod Pathol 2002 ; 15: 878–888.
22. 22 Park YB, Kim HS, Oh JH, et al.: The co‐expression of p53 protein and P‐glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop 2001 ; 24: 307–310.
23. 23 Papai Z, Feja CN, Hanna EN, et al.: P53 overexpression as an indicator of overall survival and response to treatment in osteosarcomas. Pathol Oncol Res 1997 ; 3: 15–19.
24. 24 Posl M, Amling M, Werner M, et al.: Osteosarcoma—Apoptosis and proliferation. Study of bcl‐2 expression. Pathologe 1994 ; 15: 337–344.
25. 25 Cadwell C, Zambetti GP: The effects of wild‐type p53 tumor suppressor activity and mutant p53 gain‐of‐function on cell growth. Gene 2001 ; 277: 15–30.
26. 26 Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl‐2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993 ; 74: 609–619.
27. 27 Santini D, Tonini G, Vecchio FM, et al.: Prognostic value of Bax, Bcl‐2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma. J Clin Pathol 2005 ; 58: 159–165.
28. 28 Harima Y, Nagata K, Harima K, et al.: Bax and Bcl‐2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIB cervical carcinoma. Cancer 2000 ; 88: 132–138.
29. 29 Tomazic A, Pegan V, Ferlan‐Marolt K, et al.: Cyclin D1 and bax influence the prognosis after pancreatoduodenectomy for periampullary adenocarcinoma. Hepatogastroenterology 2004 ; 51: 1832–1837.
30. 30 Pagnano KB, Silva MD, Vassallo J, et al.: Apoptosis‐regulating proteins and prognosis in diffuse large B cell non‐Hodgkin's lymphomas. Acta Haematol 2002 ; 107: 29–34.
31. 31 Xie X, Clausen OP, De Angelis P, et al.: The prognostic value of spontaneous apoptosis, Bax, Bcl‐2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999 ; 86: 913–920.
32. 32 Georgiou A, Gomatos IP, Ferekidis E, et al.: Prognostic significance of p53, bax and bcl‐2 gene expression in patients with laryngeal carcinoma. Eur J Surg Oncol 2001 ; 27: 574–580.
33. 33 Ueda Y, Dockhorn‐Dworniczak B, Blasius S, et al.: Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 1993 ; 119: 172–178.